Bayer seeks marketing approval for aflibercept 8 mg in Japan

01

March

2023

​|

07:59 AM

Europe/Amsterdam

Big News⁣ for Japan’s Health Ministry!

Summary

Get the latest on Bayer’s submission ⁢of aflibercept 8 mg for marketing authorization ‍in Japan. The submission⁣ is based upon the favorable outcomes of‍ stage III scientific trials, PULSAR and PHOTON, in which​ aflibercept 8 mg ⁢showed ⁣unmatched results against comparable treatments. Read further ‌details here.

Read More

Latest articles

Related articles